• DASH TO NASH
    Positive Results Announced in NASH Clinical Trial
  • TRAVELAN®
    US Defense Dept Study Reports Travelan® Reactivity to 180 Pathogenic Bacteria
  • The Immuron Difference
    Oral Immunotherapy for the Microbiome. A new frontier.
  • PROTECTYN®
    Help maintain digestive function and support liver health.

Clinical Insights & Updates

Positive Results in NASH Clinical Trial

Immuron Limited is today pleased to announce the topline results of its IMM-124E phase II Non-Alcoholic Steatohepatitis (NASH) clinical study. The results show that oral IMM-124E shows improvement in liver injury with the potential for far-reaching opportunities beyond NASH.

Travelan US Army Research and Clinical Studies unpacked

Travelan was the focus of a comprehensive scientific study conducted by the Department of Enteric Disease. In our Scientific Review of Travelan, we unpack the research behind this US Army study where Travelan was tested against 180 different samples of bacteria collected from personnel with travellers’ diarrhoea. In addition we outline the clinical studies conducted on Travelan in Europe and the USA.

Red Chip Analyst Upgrades Immuron on C-Difficile Trial Result

After further assessment, Red Chip analyst upgrades Immuron on C-Difficile Trial Result.

CEO Thomas Liquard at the Red Chip Global Online CEO Conference

See Immuron CEO, Thomas Liquard's presentation for Red Chip Global Online CEO Conference